Fluenz (influenza vaccine (live attenuated, nasal))
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- influenza vaccine (live attenuated, nasal)
- Company
- MedImmune LLC
- Status
- Withdrawn
- Therapeutic area
- Influenza, Human; Immunization
- EU approval
- Thu 27 Jan 2011
- Designations
- Additional monitoring
- Application
- EMEA/H/C/001101
- ATC
- J07BB03
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza in individuals 24 months to less than 18 years of age. The use of Fluenz should be based on official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Fluenz Authorised · AstraZeneca AB
- 🇪🇺 Fluenz Tetra Withdrawn · AstraZeneca AB
Follow Fluenz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.